2020
DOI: 10.1016/j.bmc.2020.115812
|View full text |Cite
|
Sign up to set email alerts
|

Bivalent HIV-1 fusion inhibitors based on peptidomimetics

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2022
2022
2023
2023

Publication Types

Select...
3

Relationship

1
2

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 53 publications
0
1
0
Order By: Relevance
“…2a). 8,9,15,[20][21][22][23] In the past two decades, we have been developing anti-HIV-1 agents including fusion inhibitors, [24][25][26][27][28] and have found that the C-terminal dimer of HIV-1 HR2 region (C34) based peptides demonstrated two orders of magnitude higher potency than the parent monomeric peptides (Fig. 2b).…”
Section: Introductionmentioning
confidence: 99%
“…2a). 8,9,15,[20][21][22][23] In the past two decades, we have been developing anti-HIV-1 agents including fusion inhibitors, [24][25][26][27][28] and have found that the C-terminal dimer of HIV-1 HR2 region (C34) based peptides demonstrated two orders of magnitude higher potency than the parent monomeric peptides (Fig. 2b).…”
Section: Introductionmentioning
confidence: 99%